Venture Philanthropists Say "Welcome To The Table" At Partnering Conference
Executive Summary
Venture philanthropists have clearly been expanding their role in funding drug development beyond the basic research phase. Now, they want to collaborate more aggressively with traditional biopharma deal-makers, and an ambitious conference, FasterCures, recently organized in New York, took a step toward that goal. The organizers created a meeting based on a mixed format, which was comfortable for its diverse attendees - patient advocates, academics, and investors - yet drove the message: let's get something done
You may also be interested in...
FDA Cites Clinical Investigator In Six Trials Of Three Cystic Fibrosis Drugs
FDA's oversight of clinical trials is becoming an increasingly significant factor in regulatory delays for some products, and a recent warning letter could have a very broad impact: it cites a clinical investigator for six trials related to three separate NDAs
FDA Cites Clinical Investigator In Six Trials Of Three Cystic Fibrosis Drugs
FDA's oversight of clinical trials is becoming an increasingly significant factor in regulatory delays for some products, and a recent warning letter could have a very broad impact: it cites a clinical investigator for six trials related to three separate NDAs
Pfizer Thinks Small: Partnership With Protalix On Gaucher Drug Eyes Cheaper Plant-Based Production
Pfizer's licensing deal with Protalix for global rights to the enzyme replacement therapy taliglucerase for the treatment of Gaucher disease, announced Dec. 1, signals the drug giant's interest in the orphan drug space. It also plays into the company's biosimilar strategy, given that taliglucerase will likely be positioned as a lower-cost alternative to Genzyme's Cerezyme (imiglucerase)